Agilent Technologies Inc. introduced the MassHunter BioConfirm application, which allows users to rapidly create targeted screening methods.
Agilent Technologies Inc. introduced the MassHunter BioConfirm application, which allows users to rapidly create targeted screening methods to characterize intact proteins and biosimilars for biopharmaceutical research, the company reports.
MassHunter BioConfirm software provides mirror plots for the comparison of biosimilars and peak modeling deconvolution to determine the molecular weight of intact proteins. The peak-modeling algorithm removes artifacts from a mass spectrum and helps resolve overlapped peaks. The resulting (simplified) spectra then allow researchers to visualize the precision of the mass measurement and ensure the accuracy of their results. This enables rapid confirmation of intact protein sequences and modifications.
Agilent’s MassHunter Workstation portfolio includes 20 individual software applications designed to optimize instrument control, data acquisition and qualitative/quantitative data analysis for Agilent’s time-of-flight, quadrupole time-of-flight, triple quadrupole, and inductively coupled plasma mass spectrometry systems.
New Cancer Research and Treatment Center in Development in London
May 1st 2025Aviva Capital Partners and developer Socius are investing £1 billion in a 12-acre site to be located at the London Cancer Hub next to The Institute of Cancer Research, London and The Royal Marsden NHS Foundation Trust’s Sutton site.